NovaBay Pharmaceuticals Reports Results from Phase 2 Clinical Trial of NVC-422 for Adenoviral Conjunctivitis

NovaBay Pharmaceuticals, Inc. NBY today announced the results of a Phase 2 clinical study for the treatment of adenoviral conjunctivitis. Of a total of 452 patients randomized 1:1 for treatment with NVC-422 ophthalmic solution or its vehicle as placebo, 81 patients were confirmed by laboratory findings to have adenoviral conjunctivitis. The predetermined primary endpoint of sustained microbiological success of 20% greater than placebo was not met. However, encouraging and unexpected results were found in the 38% of patients infected with adenovirus serotypes commonly associated with epidemic keratoconjunctivitis. An additional efficacy analysis of this subset is suggestive of positive treatment effects in clinical signs, symptoms, and microbiological findings. EKC is a highly contagious eye infection affecting both the cornea and the conjunctiva.  Importantly, a positive effect was seen for sustained clearing of blurred vision in all patients treated with NVC-422 versus placebo.